Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. TechnipFMC (FTI) downgraded to Equal Weight at Morgan Stanley with analyst Sasikanth Chilukuru saying if the current market cap of Technip Energies (THNPF) is used, rather than the firm's own fair value estimate, than there is no upside seen for TechnipFMC shares. 2. RE/MAX Holdings downgraded to Neutral from Buy at Compass Point with analyst Matthew Gaudioso saying after appreciating 34% since the company's Q3 earnings call, the stock is now trading slightly above its recent historical multiples. 3. Tabula Rasa HealthCare (TRHC) downgraded to Hold from Buy at Truist with analyst Sandy Draper saying the firm's Buy rating was predicated on steady high teens to 20% growth in CareVention and accelerating growth and margin expansion in the MedWise business, and while CareVention has been "OK," COVID is pressuring census and keeping growth muted. 4. BeiGene (BGNE) downgraded to Underperform from Outperform at CLSA with analyst Tony Ren citing a weaker sales forecast, a higher forecast for R&D spending due to the collaboration with Novartis (NVS), sentiment, and what he sees as a lack of meaningful clinical, regulatory or revenue catalysts for his cut to his rating for BeiGene. 5. Ziopharm (ZIOP) downgraded to Neutral from Buy at H.C. Wainwright with analyst Swayampakula Ramakanth seeing questions on the company's direction following the CEO change. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.